Starling Oncology™ ($STLN) is advancing oncology care by delivering highly specialized, value-based cancer care in communities across five states and growing
Starling Oncology ($STLN) reported Q2 2026 results today: revenue is up 34.6% YoY to $161.3M and Adjusted EBITDA returned to positive. We're raising full-year guidance. Full release: https://t.co/MODzev3B62
#StarlingOncology#Q2Earnings
We are now Starling Oncology™ and trading as $STLN on @Nasdaq, replacing $TOI. Same care teams, same mission. Learn more [Link to PR on website]
#StarlingOncology#Rebrand